Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Perspectives on drug withdrawals

David Rapoport
CMAJ July 19, 2005 173 (2) 128-129; DOI: https://doi.org/10.1503/cmaj.1050016
David Rapoport
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Physicians are the ultimate decision-makers in the use of prescription drugs, but we depend on the integrity of pharmaceutical companies. We spend much of our time modifying risk factors for vascular disease, but in the past few years, 2 major classes of drugs have proven to be contributors to vascular disease. The first to fall were the menopausal replacement hormones, and now we are dealing with the fallout related to COX-2 inhibitors.1

When the COX-2 drugs arrived on the scene, I actually stopped prescribing older nonsteroidal anti-inflammatory drugs, because of the risk of upper gastrointestinal bleeding. I began to have doubts about the COX-2 inhibitors when some patients experienced gastric or intestinal problems anyway, and others seemed to experience rather severe hypertension.

The drug representatives showered me with so many samples that I seldom had to write a prescription. One rep gave me an entire case, which lasted for months. I tended to favour whichever COX-2 inhibitor was in my sample cupboard, but they are a hard sell now that 2 of them have been banned. Patients read newspapers too, but surely we physicians deserve to get bad news about drugs from the manufacturers well before it hits the papers.

My fear now is that those of my patients who received COX-2 inhibitors and who now have vascular disease may question my treatment, just as my menopausal patients have questioned replacement hormone therapy. Patients are surprisingly forgiving, but there is undoubtedly a limit to their understanding.

So goes the art and practice of medicine. Sometimes when I reach for my prescription pad, I treat it like a loaded weapon, to be used with extreme caution if at all.

Reference

  1. 1.↵
    Vioxx: lessons for Health Canada and the FDA [editorial]. CMAJ 2005;172(1):5.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 173 (2)
CMAJ
Vol. 173, Issue 2
19 Jul 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Perspectives on drug withdrawals
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Perspectives on drug withdrawals
David Rapoport
CMAJ Jul 2005, 173 (2) 128-129; DOI: 10.1503/cmaj.1050016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Perspectives on drug withdrawals
David Rapoport
CMAJ Jul 2005, 173 (2) 128-129; DOI: 10.1503/cmaj.1050016
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Reference
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Final consent, advance consent and alleviating suffering in frail adults requesting MAiD
  • Should physicians rethink travel to conferences?
  • Leveling the playing field in long-term care
Show more Letters

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drugs: gastrointestinal system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire